Oramed Pharmaceuticals Inc. (ORMP) Key Metrics
ORMP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $169.3M
- Enterprise value
- $146.5M
- P/E (TTM)
- 1.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 86.6 10-yr median 60.4
- Price / book
- 0.6 10-yr median 2.8
- EV / EBITDA
- 1.9
- Dividend yield
- 6.14% $0.25 a year
- Beta
- 1.28
ORMP key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsORMP valuation Price multiples at each fiscal year-end price.
ORMP returns How much profit the business earns on the capital it uses.
ORMP per-share figures Results divided by the shares outstanding at year-end.
ORMP financial health Debt, liquidity and how easily interest is covered.
ORMP efficiency & capital use Working capital cycle and where the cash goes.
ORMP valuation history
ORMP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ORMP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ORMP cash returned to shareholders
ORMP price vs earnings per share
ORMP key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $120.9M | $98.9M | $93.7M | $469.1M | $406.5M | $87.1M | $89.9M | $44.6M | $119.8M | $77.3M |
| Enterprise value | −$4.2M | −$42.7M | −$16.7M | $314.3M | $312.9M | $47.2M | $57.6M | $14.2M | $99.7M | $46.2M |
| P/E ratio | 1.9 | — | 17.0 | — | — | — | — | — | — | — |
| Price / sales | 60.4 | — | 69.9 | 173.6 | 150.4 | 32.1 | 33.3 | 18.2 | 48.8 | 120.5 |
| Price / book | 0.6 | 0.7 | 0.6 | 3.1 | 3.5 | 2.6 | 4.6 | 1.4 | 6.2 | 3.0 |
| Price / free cash flow | — | — | — | — | — | — | — | — | — | 16.6 |
| Price / operating cash flow | — | — | — | — | — | — | — | — | — | 16.6 |
| EV / sales | -2.1 | — | -12.5 | 116.3 | 115.8 | 17.4 | 21.3 | 5.8 | 40.6 | 72.1 |
| EV / free cash flow | — | — | — | — | — | — | — | — | — | 10.0 |
| Earnings yield | 53.0% | −19.3% | 5.9% | −8.0% | −5.5% | −13.2% | −16.0% | −28.5% | −8.7% | −14.2% |
| Free cash flow yield | −9.2% | −8.5% | −11.3% | −6.2% | −5.3% | −14.4% | −14.4% | −32.8% | −4.9% | 6.0% |
| Dividend yield | 9.0% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 12.9% | 2.5% | 0.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.85 | $2.42 | $2.31 | $12.03 | $14.28 | $4.24 | $5.15 | $3.00 | $9.00 | $6.12 |
| Per share | ||||||||||
| Revenue per share | $0.05 | $0.00 | $0.03 | $0.07 | $0.09 | $0.13 | $0.15 | $0.16 | $0.18 | $0.05 |
| Earnings per share | $1.51 | −$0.47 | $0.14 | −$0.97 | −$0.78 | −$0.56 | −$0.82 | −$0.86 | −$0.79 | −$0.87 |
| Operating cash flow per share | −$0.22 | −$0.21 | −$0.25 | −$0.74 | −$0.74 | −$0.61 | −$0.74 | −$0.98 | −$0.44 | $0.37 |
| Free cash flow per share | −$0.26 | −$0.21 | −$0.26 | −$0.75 | −$0.76 | −$0.61 | −$0.74 | −$0.99 | −$0.44 | $0.37 |
| Cash per share | $2.97 | $3.47 | $3.99 | $3.99 | $3.31 | $1.94 | $1.85 | $2.05 | $1.51 | $2.46 |
| Book value per share | $4.71 | $3.58 | $4.04 | $3.89 | $4.07 | $1.60 | $1.11 | $2.09 | $1.45 | $2.07 |
| Tangible book value per share | $4.71 | $3.58 | $4.04 | $3.89 | $4.07 | $1.60 | $1.11 | $2.09 | $1.45 | $2.07 |
| Dividends per share | $0.26 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.05 | $0.00 | $0.01 | $0.01 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.02 | $0.01 | $1.27 | $0.02 | $0.02 | $0.00 | — | — | — | — |
| Shares outstanding | 42.4M | 40.9M | 40.6M | 39.0M | 28.5M | 20.5M | 17.5M | 14.9M | 13.3M | 12.6M |
| Change in shares outstanding | +3.8% | +0.7% | +4.0% | +37.0% | +38.7% | +17.6% | +17.3% | +11.8% | +5.4% | +16.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 37.0% | −12.3% | 3.5% | −28.2% | −29.9% | −44.0% | −56.8% | −50.6% | −46.1% | −43.0% |
| Return on invested capital (ROIC) | −32.3% | −34.8% | −49.5% | — | −251.5% | — | — | — | — | — |
| Return on assets (ROA) | 33.2% | −10.1% | 2.9% | −26.1% | −25.8% | −29.0% | −35.0% | −29.6% | −25.7% | −31.7% |
| Return on tangible assets | 27.7% | −12.3% | 2.5% | −23.4% | −17.4% | −25.8% | −41.4% | −26.9% | −27.1% | −25.6% |
| Free cash flow margin | −553.9% | — | −787.2% | — | −797.5% | −462.1% | −479.3% | −598.7% | −237.7% | 724.8% |
| Income quality (OCF / net income) | −0.14 | — | −1.86 | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $825,000 | $372,000 | $51.6M | $894,000 | $533,000 | $75,000 | — | — | — | — |
| Cash & short-term investments | $125.9M | $141.9M | $162.0M | $155.7M | $94.1M | $39.9M | $32.3M | $30.5M | $20.1M | $31.0M |
| Net debt | −$125.1M | −$141.6M | −$110.4M | −$154.8M | −$93.6M | −$39.8M | −$32.3M | −$30.5M | −$20.1M | −$31.0M |
| Debt / equity | 0.00 | 0.00 | 0.32 | 0.01 | 0.00 | 0.00 | — | — | — | — |
| Debt / assets | 0.00 | 0.00 | 0.23 | 0.01 | 0.00 | 0.00 | — | — | — | — |
| Net debt / EBITDA | −1.66 | — | −15.08 | — | — | — | — | — | — | — |
| Current ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 | 6.28 | 6.82 | 3.93 | 8.62 |
| Quick ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 | 6.28 | 6.82 | 3.93 | 8.62 |
| Interest coverage | — | -15.0 | -4.4 | -13.8 | — | — | -116.1 | — | — | -910.0 |
| Working capital | $114.2M | $137.5M | $109.4M | $151.4M | $88.7M | $36.0M | $28.0M | $26.5M | $15.1M | $27.6M |
| Invested capital | $74.7M | $4.7M | $53.4M | −$3.0M | $22.2M | −$6.9M | −$12.9M | $649,000 | −$884,000 | −$4.8M |
| Tangible asset value | $199.7M | $145.3M | $162.9M | $151.2M | $116.5M | $32.9M | $19.4M | $31.1M | $19.2M | $26.2M |
| Net current asset value | $102.2M | $133.3M | $104.9M | $146.6M | $83.9M | $28.8M | $18.1M | $14.8M | $823,000 | $14.6M |
| Graham number | $12.65 | — | $3.52 | — | — | — | — | — | — | — |
| Graham net-net per share | $2.32 | $3.23 | $2.57 | $3.72 | $2.90 | $1.37 | $0.97 | $0.95 | $0.05 | $1.14 |
| Capital allocation | ||||||||||
| Dividends paid | $10.9M | — | — | — | — | — | — | — | — | — |
| Share buybacks (net) | $4.7M | $2.5M | $0 | — | — | — | — | — | — | — |
| Dividend payout ratio | 17.0% | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 96.7% | — | 19.0% | 18.3% | 13.9% | 3.0% | 0.6% | 0.2% | 0.3% | 1.4% |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | — | 0.2% |
| Capex / depreciation | 15.98 | 0.09 | 1.30 | 8.55 | 4.87 | 11.71 | 1.87 | 0.83 | 1.40 | 2.25 |
| Stock-based compensation / revenue | 299.6% | — | 314.3% | 425.8% | 99.7% | 17.2% | 29.9% | 63.2% | 64.1% | 98.9% |
| R&D / revenue | 319.1% | — | 669.5% | 1,022.5% | 776.5% | 377.7% | 500.3% | 489.1% | 418.6% | 1,202.7% |
| SG&A / revenue | 436.0% | — | 628.7% | 579.4% | 219.6% | 156.2% | 137.7% | 166.7% | 112.3% | 382.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 846.1 | — | — | — | — | — | — | — | — | — |
| Days payables outstanding | 113.2 | 1,267.1 | — | — | — | 3,915.6 | 5,012.7 | 3,620.3 | 1,934.3 | 880.5 |
| Cash conversion cycle (days) | 732.9 | — | — | — | — | — | — | — | — | — |
| Receivables turnover | 0.43 | — | — | — | — | — | — | — | — | — |
| Payables turnover | 3.23 | 0.29 | 0.00 | 0.00 | 0.00 | 0.09 | 0.07 | 0.10 | 0.19 | 0.41 |
| Asset turnover | 0.01 | 0.00 | 0.01 | 0.02 | 0.03 | 0.07 | 0.07 | 0.06 | 0.06 | 0.02 |
| Average receivables | $4.6M | — | — | — | — | — | — | — | — | — |
| Average payables | $616,000 | $670,000 | $1.4M | $2.4M | $1.6M | $965,500 | $1.2M | $853,000 | $991,000 | $1.2M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ORMP's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ORMP valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Oramed Pharmaceuticals traded at 1.9 times earnings. Based on the latest twelve months, the trailing P/E is 1.0. Oramed Pharmaceuticals earned a return on equity of 37.0% and a return on invested capital of −32.3% in fiscal 2025. It ended the year with $0.8 million of debt and $125.9 million in cash and short-term investments, a net cash position of $125.1 million. It returned $15.6 million to shareholders: $10.9 million in dividends and $4.7 million in share buybacks. The share count rose 236.0% from 12.6M to 42.4M over 9 years.
See the ORMP income statement, the ORMP chart for price history, or the ORMP stock overview for the latest quote and news.
ORMP key metrics FAQ
What is Oramed Pharmaceuticals's P/E ratio?
Oramed Pharmaceuticals's trailing P/E ratio is 1.0 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was 1.9.
What is Oramed Pharmaceuticals's return on equity?
Oramed Pharmaceuticals's return on equity (ROE) was 37.0% in fiscal 2025: net income of $64.0 million on average shareholders' equity of $173.0 million.
What is Oramed Pharmaceuticals's ROIC?
Oramed Pharmaceuticals's return on invested capital was −32.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Oramed Pharmaceuticals have?
Oramed Pharmaceuticals had total debt of $0.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Oramed Pharmaceuticals's dividend yield?
Oramed Pharmaceuticals's forward dividend yield is 6.14%. Oramed Pharmaceuticals paid $10.9 million in dividends in fiscal 2025 ($0.26 per share), a payout ratio of 17.0%.
Does Oramed Pharmaceuticals buy back its shares?
Yes. Oramed Pharmaceuticals spent $4.7 million on net share repurchases in fiscal 2025 Shares outstanding changed +3.8% over the year, to 42.4M..
What is Oramed Pharmaceuticals's free cash flow yield?
Oramed Pharmaceuticals generated -$11.1 million of free cash flow in fiscal 2025, a free cash flow yield of −9.2% on its market value at year-end ($120.9 million).
What is Oramed Pharmaceuticals's current ratio?
Oramed Pharmaceuticals's current ratio was 6.98 at the end of fiscal 2025: current assets were 6.98 times current liabilities.